A modifıed poliovirus, under control of a rhinovirus promoter gene, replicates exclusively in cancer cells and appears effective against brain tumors without being neurotoxic, according to Matthias Gromeier of Duke University in Durham, N.C., and his collaborators. These treatments yield "miraculous results" in mice and appear safe when tested in phase 1 clinical trials in patients with brain tumors, he says. Gromeier presented recent fındings during the International Conference on Oncolytic Virus Therapeutics, held last April in Oxford, England.
Treatments for patients with glioblastoma (GBM) are not very effective-the chance of fıve-year survival is 5%, while patients live on average about 14 months past their diagnosis. The poliovirus receptor, nectin-like molecule-5 (Necl-5), is up-regulated in tumor cells, making them particularly susceptible to this virus, according to Gromeier. "Necl-5 expression is abundant in GBM cells and tumor-associated vasculature, and is implicated in GBM cell dispersion and invasion," he says.
Because poliovirus also infects and damages healthy nerve cells, Gromeier and his collaborators needed to strip away that capacity. They did so by swapping the polio sequence encoding the internal ribosomal entry site (IRES) for one from rhinovirus to prevent translation of poliovirus genes into proteins. The resulting chimeric virus, called PV1(RIPO), is less virulent than are attenuated poliovirus vaccine strains when evaluated in nonhuman primates, he says. Moreover, the chimeric virus produces no toxic side effects during phase 1 clinical trials, even at the highest inoculum.
PV1(RIPO) effectively destroys GBM cells within 12 hours in vitro, Gromeier says. When PV1(RIPO) was injected directly into human-derived GBM tumors that were implanted in mice, the tumors resolved in 18 of 25 animals, whereas untreated tumors continued to grow. If mice were implanted with two such tumors, a single injection of PV1(RIPO) destroyed them both, indicating the chimeric virus moves from one such tumor into another, he says.
Phase 1 clinical trials to evaluate the safety of PV1(RIPO) for humans suggest it is also effective against glioblastoma in those patients, according to Gromeier. Since 2012, only 1 of 5 treated GBM patients succumbed to tumor growth, while 2 experienced remission without other treatments. These antitumor effects may depend in part on host immune responses, he says. "The human immune system is trained to recognize virus infections and, thus, responds vigorously to the infected tumor." This means for destroying GBM might be less likely to elicit resistance than are other treatments, he points out. "The mechanism responsible for PV1(RIPO)'s effects against brain tumors broadly apply to almost all cancers," says Gromeier. "PV1(RIPO) nat-urally targets and destroys cancer cells from most common cancer types: pancreas, prostate, lung, colon, and many others."
This approach to treating patients with glioblastoma shows excellent promise, says Subbiah Elankumaran of Virginia Polytechnic Institute in Blacksburg, who is studying the Newcastle disease virus as a means for treating tumors. However, he warns, many unexpected consequences can arise when taking experimental treatments that work in mice and adapting them to treat humans.
Shannon Weiman is a freelance writer in San
Francisco, Calif.
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Methanogens Implicated in Mass Extinction 250 Million Years Ago Barry E. DiGregorio
Methane-producing Methanosarcina acetivorans microorganisms, which are found in oil wells, deep-sea hydrothermal vents, and oxygen-depleted sediments, are now implicated as being responsible for the cataclysmic PermianTriassic (PT) extinction that occurred about 250 million years ago, according to Daniel H. Rothman at the Massachusetts Institute of Technology in Cambridge, Mass., and his collaborators in the United States and China. More specifıcally, the emergence then of a new metabolic pathway "enabled effıcient conversion of marine organic carbon to methane," they report. Those metabolic changes that led to release of huge amounts of methane combined with catastrophic volcanic activity massively perturbed the atmosphere, accounting for mass extinctions everywhere on Earth, they report. Details appeared in the March 31, 2014 Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1318106111).
"The isotopic composition of carbon deposited around the time of the extinction shows that the end-Permian event is unequivocally accompanied by changes in the carbon cycle," Rothman says. "That led us to seek the cause of those changes. We focused on the dynamical behavior of the isotopic changes. This allowed us to conclude that there was an exponential, or possibly super-exponential, burst of carbon added to the oceans and atmosphere."
Geologists and other scientists long speculated that a surge in volcanic activity could account for the PT extinctions. However, isotopic changes during that period are not consistent with volcanic activity accounting for such a burst, according to Rothman and his collaborators, who reasoned that microbial communities are capable of exponential, or faster, growth. "Having made that realization, we then investigated the genomic record of microbial evolution," he says. Their fırst efforts were to determine more precisely when Methanosarcina, with its effıcient metabolic pathway for producing methane and acetate from carbon monoxide, likely emerged.
Rothman's team used a combination of carbon isotopic analysis, phylogenetics, nickel analyses, and mathematical arguments to arrive at their conclusion. Each exhibited their own technical diffıculties. "In many respects the hardest part of this work is the linkage of the disparate parts into a coherent hypothesis that not only makes sense mech- anistically but also explains a signifıcant number of observations," he says.
MINITOPIC
First
Methanosarcina bloomed explosively, spewing prodigious amounts of methane into the atmosphere, dramatically changing the climate as well as the chemistry of the oceans. Meanwhile, massive volcanism led nickel levels in sediments to increase abruptly. Nickel is an essential component of a key enzyme of methanogens, and the surge in availability of this metal was crucial for the Methanosarcina bloom, according to Rothman.
"The ideas presented in the Rothman paper are not unreasonable, but I think it is fanciful to think that microbes 'caused' the PT extinction," says David Bond from the University of Hull in the United Kingdom. "Maybe they played a part in the predicted volcanism-climate change-anoxia-extinction scenario, but we are still a long way from understanding the actual causes of this event." He also says that the new hypothesis provides a "highly plausible mechanism for generating observed carbon isotopic shifts."
Barry E. DiGregorio is a freelance writer in Middleport, N.Y.
PUBLIC HEALTH
Rules from 2005 Ease Matters for Officials Coping with Outbreaks Jeffrey L. Fox
With their 10th anniversary looming, the International Health Regulations (IHR) of 2005 are gathering plenty of praise these days-a rarity for rules affecting practically every country on the planet. Thus, despite diffıculties in implementing these rules and applying common standards to disparate countries, IHR 2005 is "widely accepted" among the nearly 200 countries that signed the document, according to Keiji Fukuda of the World Health Organization (WHO), which is charged with implementing the rules. He spoke during a two-day workshop, "Emerging Viral Diseases-the One Health Connection," convened by the Institute of Medicine (IOM) Forum on Microbial Threats and held in Washington, D.C., last March.
The IHR rules, which are meant "to prevent, protect against, control, and provide a public health response to the international spread of disease in ways that are commensurate with and restricted to public health risks, and which avoid unnecessary interference with international traffıc and trade," require countries to "report certain disease outbreaks and public health events to WHO." The rules also require countries to "strengthen core surveillance and response capacities at the primary, intermediate, and national level. . . ."
The H1N1 influenza pandemic, whose initial outbreaks occurred early in 2009 fırst in Mexico and then in California, provided the fırst test of IHR 2005 and led to its fırst formal review the following year, according to IOM President Harvey Fineberg. He was one of 24 experts from as many countries who served on a World Health Assembly (WHA) committee to conduct that review. One "special challenge" for the committee was to hold its meetings open to the public, heading off criticisms that "WHO was being secretive," he says.
The WHA committee came to several key conclusions about IHR 2005, according to Fineberg. First, the new rules "helped the world be better prepared" to cope with emerging diseases, even though many countries still fall short in terms of their core capacities for dealing with such emergencies, he says. Another issue is that, although IHR 2005 rules are binding, enforcement measures are lacking and, instead, depend on what can be negotiated with or cajoled from each country.
MINITOPIC
WHO Documents Antibiotic Resistance, Polio, Ebola Outbreaks
World Health Organization (WHO) officials recently issued several reports with warnings on worldwide antibiotic resistance, a resurgence of polio, and a major outbreak of Ebola virus in West Africa:
• In April, WHO officials released a comprehensive report on antibiotic resistance, "Antimicrobial resistance: global report on surveillance," featuring data from 114 countries and providing a global overview as well as region-by-region analyses of drug resistance patterns. It calls drug resistance a "major threat to public health" and says that WHO is seeking "improved collaboration around the world to track drug resistance, measure its health and economic impacts, and design targeted solutions." WHO takes great pains not to embarrass individual countries for how well or poorly they "measure up," and this low-key approach ends up being a "core problem," Fineberg says. Although the idea of WHO helping in efforts to assess a country's capacity to deal with emerging infectious diseases "makes sense, national governments don't like it," Fukuda adds, noting that only about 20% of the countries have the appropriate capacity. "WHO is well-positioned to help with quality assessments, but we haven't found the right way to achieve the necessary political balance."
Another looming issue is how best to deal with the Convention on Biological Diversity (CBD), an international agreement from 1992 that was never intended to deal with public health issues. Nonetheless, some of its provisions bump into matters concerning IHR 2005, particularly when it comes to sharing of biological materials that, for example, might prove critical for the development of diagnostic tests and vaccines. "What can you do?" Fukuda asks. "This framework [the CBD] is seen as being 'over there,' having nothing to do with health, but we realize it does."
Jeffrey L. Fox is the Microbe Current Topics and Features Editor.
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Freely Diffusing Topical Antifungal Agent Fixes Infected Toenails David C. Holzman
The candidate antifungal drug efına-conazole is proving effective against toenail infections. The drug diffuses relatively freely through nails and binds less strongly to keratin than do other topically applied antifungal drugs, leaving it free to fıght the fungus, according to Keita Sugiura of Kaken Pharmaceutical of Kyoto, Japan, and his collaborators. "This study suggests that . . . low keratin affınity is needed for favorable penetration and retention of antifungal activity within the nail matrix," he says. Details appeared online 21 April 2014 and will be printed in the July 2014 Antimicrobial Agents and Chemotherapy.
Because topical antifungal drugs so often fail to cure this condition, physicians sometimes prescribe oral antifungal drugs such as terbinafıne and itraconazole for some of their patients with stubborn cases of onychomycosis. However, Sugiura points out, this approach "is limited" because such drugs can damage the liver or may interact with other drugs that patients are taking. Although topically applied antifungal drugs such as ciclopirox and amorolfıne have "a favorable safety profıle," he adds, "their cure rates are considerably lower." Sugiura and his collaborators tested human nails to fınd how well the drug diffuses through keratin-rich nails. Small 16 mm 2 squares from commercially available toenail material (who knew?) were mounted in Franz diffusion cells to measure how quickly several antifungal drugs pass through that material. Efınaconazole proved speediest, racing through the mounted nail squares within the fırst day, while ciclopirox took six days and amorolfıne remained undetected, they report.
Of several drugs tested, only efına-conazole inhibited fungal growth under nails in vitro, according to Sugiura. He and his collaborators also tested the fungicidal activity of several topical antifungal products in a fluid keratin medium that is designed to "mimic the keratin-rich environment of the nail plate and nail bed." Without a solid matrix to block the drugs, efınaconazole proved slightly more potent at killing
MINITOPIC
Shapes and Curves; Plus Revised View of Cell-Wall Growth
The shapes of microbial species are sometimes fanciful and can be important for their survival or may mask activities that are key to physiology. Recent examples include:
• Helicosporidium, a corkscrew-shaped intracellular parasite that feeds on juvenile insects, derived from algae but, unlike Plasmodium, the parasite responsible for malaria which also derived from algae, retained most of its genes except those explicitly needed for photosynthesis, according to Microbe-Volume 9, Number 7, 2014 • 267 the fungus than did amorolfıne and far more potent than ciclopirox, they note. "Efınaconazole is the fırst topical drug that has shown effıcacy for this persistent and common infection," says Boni Elewski of the University of Alabama, Birmingham, who last year led a pair of phase 3 clinical studies to evaluate this drug for treating onychomycosis, the formal name for chronic fungal infections of toenails. "I think this mechanism of action is indeed quite signifıcant, contributing to the relatively high mycologic cure rate in treating onychomycosis," says Elewskii.
The typical fungi responsible for onychomycosis include Trichophyton rubrum, T. mentagrophytes, Candida albicans, and nondermatophyte molds. The condition affects about 8% of the U.S. population, mainly adults, particularly those who are 60 years of age or older. While more a cosmetic than a frank health issue, onychomycosis can prove painful as well as being an eyesore, and may interfere with work that entails standing, food handling, modeling, or other interactions and relationships, Elewski points out.
David C. Holzman is the Microbe Journal Highlights Editor.
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Promising Tuberculosis Drug also Targets Vastly Different Microbes Carol Potera
A promising candidate drug for treating tuberculosis (TB), called SQ109 and undergoing phase 2 clinical trials, acts against Mycobacterium tuberculosis as well as other microbial pathogens and parasites via several different mechanisms, according to Eric Oldfıeld at the University of Illinois, Urbana-Champaign, and his collaborators. Not only SQ109, but also a series of analogues inhibit the growth of a range of microorganisms, acting at various molecular targets-leading to "very low rates of spontaneous drug resistance," they report. "There's an urgent need for new drugs that are resistance-resistant, and drugs that hit multiple targets will reduce resistance," Oldfıeld adds. Details appeared February 25, 2014 in the Journal of Medicinal Chemistry (doi:10.1021/jm500131s).
SQ109 is a 1,2-diamine that is related to ethambutol, a widely used drug that is bacteriostatic against M. tuberculosis, blocking cell-wall production. Sequella, Inc. in Rockville, Md., a company focused on TB, began developing SQ109 in 2000, then in partnership with researchers at the National Institutes of Health (NIH) in nearby Bethesda, Md. Several years ago, members of the NIH group and their collaborators reported that SQ109 "interferes with the assembly of mycolic acids into the cell wall core of M. tuberculosis." They also concluded that the primary bacterial target for the drug was MmpL3, "a transporter of trehalose monomycolate," an ingredient of the cell wall in M. tuberculosis.
That seeming clarity for how SQ109
and analogues like it work, however, proved to be less than complete. Other researcher groups reported that SQ109 acts against other microbial species, including Helicobacter pylori bacteria and Candida albicans, a yeast. Two of the analogues are 4 to 5 times more potent than is SQ109 against M. tuberculosis in vitro, and one of them is 4 times less toxic against the human cell line. The compounds show varied activity against the other bacteria, yeasts, and P. falciparum-in general, targeting several different enzymes, including ones involved in menaquinone biosynthesis, electron transport, and inhibition of ATP biosynthesis.
"SQ109 and related compounds may be acting by a combination of mutually reinforcing mechanisms," says Julio Urbina, emeritus investigator at the Venezuelan Institute for Scientifıc Research, near San Antonio de los Altos in Altos de Pipe, Miranda State. "This may explain their potency and suggests that they could represent a novel class of broad-spectrum anti-infective drugs, active against bacterial, fungal, and protozoan pathogens." "I hope the pharmaceutical industry, which has shown a distressing lack of interest in the discovery of antibiotics, will be stimulated by work like Oldfıeld's," says Andrew McCammon, a Howard Hughes Medical Institute Investigator and distinguished professor of pharmacology at the University of California, San Diego. Another plus, he adds, is that these antibiotic candidates have "the remarkable property of inhibiting not just one, but several essential cellular functions in pathogenic bacteria, fungi, and the malaria parasite." Such antimicrobial products, if used clinically, thus might be less prone to stimulating the development of drug resistance in pathogens.
Carol Potera is a freelance writer in Great Falls, Mont. 
NEW IN ASM JOURNALS
Evolution of Equine Influenza Virus Led to Canine Offshoot
NEW IN ASM JOURNALS
Fermentation of Cocoa Beans Requires Precise Collaboration among Two Bacteria and Yeast
One can always work to make a good thing better. That spirit motivated a team of researchers who investigated cocoa bean fermentation.
The key molecule to initiate flavor development is acetate, says PI Christoph Wittmann, of Saarland University, Saarbruecken, Germany. Production of acetate requires two major nutrients: lactate and ethanol. These are produced by lactic acid bacteria and yeast, respectively, during the initial fermentation of cocoa pulp sugars, says Wittmann. He and his collaborators show, in a lab simulation of cocoa fermentation, that the acetic acid bacteria then process the two compounds simultaneously, via separate metabolic pathways, and then produce
